Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
CAR-TCR Summit Europe 2019

CAR-TCR Summit Europe 2019

Categories

Date of beginning

Monday, 25 February 2019

Duration

3 days

City

Greater London

Country

United Kingdom

Contact

Aarti Diwan

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

The CAR-TCR Summit Europe is your opportunity to join the expert CAR and TCR pioneers to learn about never-before-seen clinical updates and novel technology to improve solid tumour targeting, advance allogeneic therapy development and automate manufacturing processes to reduce the cost of goods. If you are looking to initiate clinical trials in Europe, join us to navigate the complex regulations and reimbursement landscape to understand and overcome market access challenges. And if you are looking to drive progress in scientific discovery, join us as we discuss novel breakthroughs with innovations with gamma delta and NKT cells, innovative antigen screening platforms and genetic engineering strategies to create, translate and develop the next generation of CAR and TCR therapies.   URLs:Tickets: https://go.evvnt.com/317792-2?pid=5569 Brochure: https://go.evvnt.com/317792-3?pid=5569  Date and Time: On Monday February 25, 2019 at 8:00 am ends Wednesday February 27, 2019 at 5:00 pm Venue details: Novotel London West, 1 Shortlands, Greater London, W6 8DR, United Kingdom Prices:Conference + Workshop Day: GBP 2498.0,Conference Only: GBP 1699.0,Conference + Workshop Day (Early Bird ends Friday 25th January, 2019): GBP 2398.0,Conference Only (Early Bird ends Friday 25th January, 2019): GBP 1599.0 Speakers: Dale Ludwig, Chief Scientific Officer, Actinium Pharmaceuticals, Barbra Sasu, Chief Scientific Officer, Allogene Therapeutics, Christian Itin, Chief Executive Officer, Autolus, Vicki Coutinho, Senior Director, Regulatory Affairs, Autolus, Jie Jia, Vice President, Strategic Alliances CARsgen Therapeutics, Zonghai Li , Chief Executive Officer, CARsgen Therapeutics, Tony Ho Executive Vice President, Head of Research and Development, CRISPR Therapeutics, Stefanos Theoharis, Senior Vice President, Corporate Development and Partnering, Cell Medica, Stephane Depil, Senior Vice President Research and Development and Chief Medical, Cellectis, David Gilham, Vice President, Research and Development, Celyad, Detlev Parow Head of Department of Medicines, Therapeutic Appliances and Remedies Product and Billing Management Division, DAK-Gesundheit, Bob Valamehr Chief Development Officer and Vice President Cancer Immunotherapy, Fate Therapeutics, Cedrik Britten, Head of Oncology Cell Therapy Research Unit, GSK, Harpreet Singh, Chief Executive Officer, Immatics US, Will Singleterry Associate Director, Business Development, Isoplexis, Marc Kamp Director CAR-T Product Distribution and Supplier Quality Management, Kite Pharma, John Maher, Chief Scientific Officer, Leucid Bio, Juan Vera, Chief Development Officer, Marker Therapeutics, Peter L. Hoang, President and Chief Executive Officer, Marker Therapeutics, Dolores Schendel, Chief Executive Officer and Chief Scientific Officer, Medigene, Kai Pinkernell, Chief Medical Officer and Chief Development Officer, Medigene, James McBlane Preclinical Assessor, MHRA and Member, Committee for Advanced Therapies (CAT), EMA, Katharina Winnemöller, Marketing Manager for Clinical Cell Processing and T Cell Applications, Miltenyi Biotec, Pilar Pinilla Dominguez Senior Scientific Adviser, NICE, Therese Choquette Analytical Project Leader, Cell and Gene Therapy Development and Manufacturing, Novartis, Francesco Marincola, Chief Scientific Officer, Refuge Biotech, Jim Freeth Co-managing Director, Retrogenix, Véronique Blanc Immuno-Oncology Program Director, Servier, Michael Leek, Chief Executive Officer, TC Biopharm, Alfonso Quintás Cardama, Chief Medical Officer, TCR2 Therapeutics, Dan Ollendorf, Director Value Measurement and Global Health Initiatives, Tufts University Center for the Evaluation of Value and Risk in Health, CEVR, Qasim Rafiq, Senior Lecturer in Bioprocessing of Regenerative, Cellular and Gene Therapy, UCL, Miguel Forte Chief Executive Officer, Zelluna Immunotherapy, Laurence Cooper, Chief Executive Officer, Ziopharm Oncology, Jens Hasskarl, Senior Director, Research Development, Clinical and Medical, Celgene Corporation, Maureen Graham, Managing Director, Diamond Pharma Services, Andreas Göbel Executive and Technology Lead, Hypertrust Patient Data Care, Kai Wilkens, Senior Director Europe ACD, Bio-Techne